What is the appropriate management of ascites in a patient with chronic liver disease?

Management of Ascites in Chronic Liver Disease

First-line treatment consists of dietary sodium restriction to ≤5 g/day (88 mmol/day) combined with oral diuretics—spironolactone starting at 50-100 mg/day (up to 400 mg/day) with or without furosemide 20-40 mg/day (up to 160 mg/day) 1.

Initial Assessment and Diagnosis

All patients with new-onset ascites require diagnostic paracentesis to:

• Calculate serum-ascites albumin gradient (SAAG ≥1.1 g/dL confirms portal hypertension)
• Obtain cell count with differential to rule out spontaneous bacterial peritonitis (SBP)
• Perform Gram stain and culture (inoculate blood culture bottles at bedside)
• Measure ascitic fluid total protein and albumin 1

Critical pitfall: Infection must be ruled out at every hospital admission as SBP carries high mortality risk and requires immediate empirical antibiotics (cefotaxime widely studied, but choose based on local resistance patterns) 1.

Stepwise Treatment Algorithm

Grade 2 Ascites (Moderate)

1. Sodium restriction: Maximum 5-6.5 g salt/day (no added salt, avoid precooked meals) 1
2. Spironolactone monotherapy: Start 100 mg daily, increase to 400 mg as needed 1
3. Add furosemide if faster diuresis needed or for hospitalized patients: Start 40 mg daily, increase to 160 mg 1
4. Protein supplementation: 1.2-1.5 g/kg/day recommended 2

Fluid restriction is NOT necessary unless serum sodium <120-125 mmol/L 3, 1. This is a common misconception—most patients do not require fluid restriction.

Grade 3 Ascites (Tense/Severe)

1. Initial large-volume paracentesis (LVP) for rapid symptom relief 3
2. Then initiate sodium restriction and diuretics as above 3, 4

Monitoring During Diuretic Therapy

• Target weight loss: 0.5 kg/day without peripheral edema; no strict limit with edema present 2
• Monitor electrolytes, creatinine, and body weight regularly 4
• Reduce or stop diuretics if:
  • Hypokalemia develops (reduce loop diuretic) 2
  • Hyperkalemia develops (reduce aldosterone antagonist) 2
  • Severe hyponatremia, acute kidney injury, overt hepatic encephalopathy, or severe muscle cramps occur 2

Refractory Ascites Management

Refractory ascites is defined as fluid overload that either:

1. Fails to respond to maximum diuretics (spironolactone 400 mg + furosemide 160 mg) with sodium restriction, OR
2. Recurs rapidly after therapeutic paracentesis 2, 3

Treatment options in order of preference:

Serial Large-Volume Paracentesis

• Albumin infusion: 6-8 g per liter of ascites removed when >5 L drained 2, 1
• For <5 L removal, consider albumin in patients with acute-on-chronic liver failure (ACLF), hypotension, renal insufficiency, or electrolyte abnormalities 1, 5
• Ultrasound guidance reduces adverse events 1
• No routine need for checking coagulation parameters or transfusing blood products before paracentesis 1

Transjugular Intrahepatic Portosystemic Shunt (TIPSS)

TIPSS should be considered for refractory ascites 1, 3, 1, but exercise caution with:

• Age >70 years
• Bilirubin >50 μmol/L (approximately 3 mg/dL)
• Platelet count <75×10⁹/L
• MELD score ≥18
• Current hepatic encephalopathy
• Active infection or hepatorenal syndrome 1

The 2021 BSG/BASL guidelines provide the most recent evidence supporting TIPSS as high-quality recommendation for refractory ascites 1.

Special Considerations

Albumin Administration Beyond Paracentesis

The 2018 KASL guidelines note that albumin administration:

• Increases diuretic response and reduces hospitalization
• Reduces mortality in meta-analyses
• Reduces hepatorenal syndrome in SBP (1.5 g/kg at diagnosis, 1 g/kg at day 3 for high-risk patients with bilirubin >4 mg/dL or creatinine >1 mg/dL) 2

However, long-term weekly albumin remains controversial with conflicting trial results 4.

Medications to AVOID

• NSAIDs (convert diuretic-sensitive to refractory ascites) 3, 4
• ACE inhibitors and ARBs 4
• Aminoglycosides when possible 4

Liver Transplantation

All patients with grade 2 or 3 ascites should be considered for liver transplant evaluation 3, 4. Development of ascites marks transition to decompensated cirrhosis with 20% mortality in first year 1.

Palliative Care

Patients with refractory ascites not undergoing transplant evaluation should receive palliative care referral, with repeated LVP as primary palliative treatment 1.

The most recent and comprehensive guidance comes from the 2021 BSG/BASL guidelines 1 and the 2021 AASLD Practice Guidance 4, which align closely on core recommendations while the 2025 AGA Clinical Practice Update 5 reinforces these evidence-based approaches.